A novel vaccine against vaginal Chlamydia trachomatis

描述(由申请人提供)：预防沙眼衣原体(CT)感染是一个严重的未得到满足的医疗需求。开发一种有效的疫苗不仅可以减少与这些感染相关的发病率，包括盆腔炎、不孕不育、慢性盆腔疼痛和宫外孕，而且还可以减少包括艾滋病毒传播在内的附带风险。尽管经过几十年的努力，目前还没有疫苗可用。生产有效疫苗的能力受到以下因素的限制：1)缺乏一种有效的方法来传递将引起保护性体液和细胞介导性反应的抗原，以及2)识别特定的抗原序列，以保护个人免受引起性传播疾病(STD)的CT菌株的伤害。由EbitoGenesis，Inc.开发的专有营养免疫增强递送系统(NIDS)和Dean实验室进行的广泛的序列评估，加上关于CT和HIV-1疫苗结构的令人兴奋的初步数据，提供了一个独特的机会，最终获得一种有效的疫苗，通过使用与新颖、安全和有效的NID组成的新型抗原结构来预防CT的阴道传播，用于粘膜和全身疫苗接种。此外，黏膜和全身免疫途径的组合、缺乏与人类抗原的序列同源性，以及来自EbitoGenesis和Dean实验室的有希望的初步结果，保证了一种新的疫苗设计和接种方法，这些方法有望获得成功。 公共卫生相关性：Deborah Dean博士开发的专有沙眼衣原体(Ct)抗原结构，以及EbitoGenesis开发的营养免疫增强递送系统(NIDS)，为开发能够预防沙眼衣原体(CT)阴道传播的有效疫苗提供了独特的机会。

DESCRIPTION (provided by applicant): Preventing Chlamydia trachomatis (Ct) infections represent a critical unmet medical need. Development of an effective vaccine would not only reduce the morbidity associated with these infections, including pelvic inflammatory disease (PID), infertility, chronic pelvic pain and ectopic pregnancy, but could also reduce collateral riss including HIV transmission. Despite decades of efforts, no vaccine is currently available. The ability to generate a useful vaccine has been limited by 1) the lack of an effective method to deliver antigens that will elicit protective humeral and cell-mediated responses, and 2) the identification of specific antigenic sequences that would protect individuals from the Ct strains that cause sexually transmitted diseases (STD). The proprietary nutritive immune-enhancing delivery system (NIDS) developed by EpitoGenesis, Inc. and the broad-based sequence assessment performed by the Dean lab, in addition to the exciting preliminary data on an Ct and HIV-1 vaccine constructs, provide a unique opportunity to finally obtain an efficacious vaccine that can protect against vaginal transmission of Ct through the use of the novel antigenic constructs formulated with the novel, safe and effective NIDS for mucosal and systemic vaccinations. Furthermore, combinations of mucosal and systemic vaccination routes, lack of sequence homology to human antigens, and promising preliminary results from both EpitoGenesis and the Dean lab warrant a novel vaccine design and vaccination approach that hold promise of success. PUBLIC HEALTH RELEVANCE: The proprietary, Chlamydia trachomatis (Ct) antigenic constructs developed by Dr. Deborah Dean, and the nutritive immune-enhancing delivery system (NIDS) developed by EpitoGenesis, provide a unique opportunity to develop an efficacious vaccine that can protect against vaginal transmission of Ct.